Meeting
2015 ASCO Annual Meeting
A phase I study to evaluate the safety and tolerability of MEDI4736, an anti- programmed cell death-ligand-1 (PD-L1) antibody, in combination with tremelimumab in patients with advanced solid tumors.
Authors
Patrick Alexander Ott
Dana-Farber Cancer Institute, Boston, MA
Patrick Alexander Ott , Margaret K. Callahan , Kunle Odunsi , Andrew J. Park , Linda S. Pan , Ralph Rudolph Venhaus , Joyson Joseph Karakunnel , F. Stephen Hodi , Jedd D. Wolchok
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Immunotherapy and Biologic Therapy
Clinical Trial Registration Number
NCT01975831
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS3099)
DOI
10.1200/jco.2015.33.15_suppl.tps3099
Abstract #
TPS3099
Poster Bd #
419a
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti–PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors.
First Author: Margaret K. Callahan
Poster
2018 ASCO Annual Meeting
Preliminary interim results of the first-in-human, dose-finding PROCLAIM-CX-072 trial of the PD-L1 Probody therapeutic (Pb-Tx) CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors.
First Author: Rachel E. Sanborn
Poster
2017 ASCO Annual Meeting
Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, DUR) + tremelimumab (TRE) in patients with advanced solid tumors.
First Author: Margaret K. Callahan
Poster
2016 ASCO Annual Meeting
A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors.
First Author: Jayesh Desai